Decision: Favourable

Study Title:

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Declan O'Rourke

  • PI Institution:

    Children's Health Ireland at Temple Street

  • Sponsor:

    Dyne Therapeutics, Inc.

Scroll to Top